ReviewCancer immunity2007
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer.
Review in Cancer immunity, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Prognostic value of the controlling nutritional status (CONUT) score in patients with diffuse large B-cell lymphoma: a meta-analysis.World journal of surgical oncology · 2025Pooled it
- The landscape of genitourinary cancer vaccines: clinical advances and future opportunities.Journal of advanced research · 2026Review
- Multidimensional explanations and future perspectives on the limited efficacy of immunotherapy in prostate cancer.Asian journal of andrology · 2026Review
- Bladder cancer biomarkers: current approaches and future directions.Frontiers in oncology · 2024Review
- Targeted therapies in bladder cancer: signaling pathways, applications, and challenges.MedComm · 2023Review
- Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer.BMC cancer · 2023Article
- Inflammation in Urological Malignancies: The Silent Killer.International journal of molecular sciences · 2023Review
- Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer.Therapeutic advances in medical oncology · 2023Review
- Prognostic evaluation of preoperative systemic immune inflammatory index in patients with colorectal cancer.Frontiers in oncology · 2023Article
- Article
- Identification of the Tumor Infiltrating Lymphocytes (TILs) Landscape in Pure Squamous Cell Carcinoma of the Bladder.Cancers · 2022Article
- Copy number variation analysis of mCancer medicine · 2021Article
- Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma.IJU case reports · 2021Article
- Prognostic role of the systemic immune-inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration.Cancer immunology, immunotherapy : CII · 2021Article
- Clinicopathological factors associated with tumor-infiltrating lymphocyte reactivity in breast cancer.Cancer immunology, immunotherapy : CII · 2020Article
- Article
- Identification of Let-7f-5p as a novel biomarker of recurrence in non-muscle invasive bladder cancer.Cancer biomarkers : section A of Disease markers · 2020Article
- Article
- Chorioallantoic urothelial tumor avatar. A clinical tool for phenotype-based therapy.Acta cirurgica brasileira · 2020Review
- Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.The Journal of pathology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The idea of generating cytotoxic T-lymphocytes that have anti-tumor activity has been the focus of many clinical trials aimed at delivering effective immunotherapy to cancer patients. We have gained insight into the human immune system in cancer patients as a result of these numerous clinical investigations. It is now clear that although various vaccination methods are capable of inducing tumor antigen-specific T-cells in the circulating blood, these immunological responses are infrequently correlated with clinical responses. Therefore, it appears that priming of a T-cell response is not sufficient for tumor regression and other avenues, downstream of the priming phase, need to be investigated. Mechanisms of immune evasion at the effector phase of the anti-tumor phase are currently under investigation, with an increasing focus on the tumor microenvironment. There is evidence indicating that multiple variables may contribute to immune escape, including: regulatory cells; inhibitory ligands on tumor cells, such as PD-L1 and B7x; soluble factors such as TGF-beta and IL-10; and nutrient-catabolizing enzymes, such as indoleamine-2,3-dioxygenase (IDO). In addition, there are ongoing efforts to assess the presence and function of effector cells within the tumor microenvironment. Tumor infiltrating lymphocytes (TILs) have been observed in patients with melanoma, colon cancer, and ovarian cancer. TILs in these patients have been associated with favorable clinical outcomes. In the clinical setting of bladder cancer, as compared to melanoma, there is limited data regarding TILs. This review will focus on immunological responses to bladder cancer and ongoing studies to identify factors that are amenable to therapeutic manipulation.
Indexed as
Identifiers
17591743PMC2935746W99862688What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.